Advanced search
Publication Cover
Neurodegenerative Disease Management Volume 6, 2016 - Issue 3
Submit an article Journal homepage
1,464
Views
0
CrossRef citations to date
0
Altmetric
Editorial

Aβ Immunotherapy for Alzheimer’s Disease: Where are we?

Jofre Güell-Bosch1 Protein Folding & Stability Group Departament de Bioquímica i Biologia Molecular Unitat de Biociències Universitat Autònoma de Barcelona Campus Bellaterra 08193Cerdanyola del VallèsSpain
,
Laia Montoliu-Gaya1 Protein Folding & Stability Group Departament de Bioquímica i Biologia Molecular Unitat de Biociències Universitat Autònoma de Barcelona Campus Bellaterra 08193Cerdanyola del VallèsSpain
,
Gisela Esquerda-Canals1 Protein Folding & Stability Group Departament de Bioquímica i Biologia Molecular Unitat de Biociències Universitat Autònoma de Barcelona Campus Bellaterra 08193Cerdanyola del VallèsSpain
&
Sandra Villegas1 Protein Folding & Stability Group Departament de Bioquímica i Biologia Molecular Unitat de Biociències Universitat Autònoma de Barcelona Campus Bellaterra 08193Cerdanyola del VallèsSpainCorrespondence[email protected]
Pages 179-181 | Received 18 Jan 2016, Accepted 25 Jan 2016, Published online: 27 May 2016

References

  • Prince M , WimoA, GuerchetM, AliG-C, WuY-T, MatthewP . The Global Impact of Dementia. An analysis of prevalence, incidence, costs and trends. World Alzheimer Report ( 2015 ). www.alz.co.uk/research/world-report-2015 .
  • Terry RD , MasliahE, SalmonDPet al. Physical basis of cognitive alterations in Alzheimer’s disease: synapse loss is the major correlate of cognitive impairment . Ann. Neurol.30 ( 4 ), 572 – 580 ( 1991 ).
  • Clinical Trials NIH database . https://clinicaltrials.gov/ .
  • Gilman S , KollerM, BlackRSet al. Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial . Neurology64 ( 9 ), 1553 – 1562 ( 2005 ).
  • Bard F , CannonC, BarbourRet al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease . Nat. Med.6 ( 8 ), 916 – 919 ( 2000 ).
  • Salloway S , SperlingR, FoxNCet al. Two Phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease . N. Engl. J. Med.370 ( 4 ), 322 – 333 ( 2014 ).
  • La Porte SL , BolliniSS, LanzTAet al. Structural basis of C-terminal β-amyloid peptide binding by the antibody ponezumab for the treatment of Alzheimer’s disease . J. Mol. Biol.421 ( 4–5 ), 525 – 536 ( 2012 ).
  • Doody RS , ThomasRG, FarlowMet al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease . N. Engl. J. Med.370 ( 4 ), 311 – 321 ( 2014 ).
  • Ostrowitzki S , DeptulaD, ThurfjellLet al. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab . Arch. Neurol.69 ( 2 ), 198 – 207 ( 2012 ).
  • Adolfsson O , PihlgrenM, ToniNet al. An effector-reduced anti-β-amyloid (Aβ) antibody with unique Aβ binding properties promotes neuroprotection and glial engulfment of Aβ . J. Neurosci.32 ( 28 ), 9677 – 9689 ( 2012 ).
  • Sevigny J , ChiaoP, WilliamsL, MiaoX, O’GormanJ . Randomized, double-blind, Phase 1b study of BIIB037, an anti-amyloid beta monoclonal antibody, in patients with prodromal or mild Alzheimer’s disease . 12th International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders . Nice, France, 18 March–22 March 2015 .
  • Lannfelt L , MöllerC, BasunHet al. Perspectives on future Alzheimer therapies: amyloid-β protofibrils – a new target for immunotherapy with BAN2401 in Alzheimer’s disease . Alzheimers Res. Ther.6 ( 2 ), 16 ( 2014 ).
  • Ravetch J , FukuyamaH . Antibodies specific for the Protofibril Form of Beta-Amyloid Protein. US Patent WO 2009065054 A2 ( 2009 ).
  • Underwood E . Neuroscience. Alzheimer’s amyloid theory gets modest boost . Science349 ( 6247 ), 464 ( 2015 ).
  • Reardon S . Antibody drugs for Alzheimer’s show glimmers of promise . Nature523 ( 7562 ), 509 – 510 ( 2015 ).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.